An integrated approach to cardioprotection in lymphomas
Maraldo, M. V. Levis, M. Andreis, A. Armenian, S. Bates, J. Brady, J. Ghigo, A. Lyon, A. R. Manisty, C. Ricardi, U.
Maraldo, M. V.
Levis, M.
Andreis, A.
Armenian, S.
Bates, J.
Brady, J.
Ghigo, A.
Lyon, A. R.
Manisty, C.
Ricardi, U.
Citations
Altmetric:
Abstract
In potentially curable cancers, long-term survival depends not only on the successful treatment of the malignancy but also on the risks associated with treatment-related toxicity, especially cardiotoxicity. Malignant lymphomas affect patients at any age, with acute and late toxicity risks that could have a severe effect on morbidity, mortality, and quality of life. Although our understanding of chemotherapy-associated and radiotherapy-associated cardiovascular disease has advanced considerably, new drugs with potential cardiotoxicity have been introduced for the treatment of lymphomas. In this Review, we summarise the mechanisms of treatment-related cardiac injury, available clinical data, and protocols for optimising cardioprotection in lymphomas. We discuss ongoing research strategies to advance our knowledge of the molecular basis of drug-induced and radiation-induced toxicity. Additionally, we emphasise the potential for personalised follow-up and early detection, including the role of biomarkers and novel diagnostic tests, highlighting the role of the cardio-oncology team.
Description
Date
2022
Publisher
Collections
Keywords
Type
Article
Citation
Maraldo MV, Levis M, Andreis A, Armenian S, Bates J, Brady J, et al. An integrated approach to cardioprotection in lymphomas. Vol. 9, The Lancet Haematology. Elsevier BV; 2022. p. e445–54.